Liraglutide Significantly Reduced Liver Fat, Visceral Fat, and Blood Sugar in Chinese Obese Patients Over 12 Weeks | Research

The takeaway

12 weeks of liraglutide monotherapy significantly reduced liver fat content, visceral and subcutaneous abdominal fat, and improved glucose metabolism in 71 Chinese obese subjects, with liver fat reduction correlating strongly with blood sugar improvement.

Liver fat-glucose correlation r=0.607
Liver fat reduction from liraglutide was strongly correlated with HbA1c improvement (r=0.607), suggesting that reducing liver fat is a key mechanism by which GLP-1 medications improve glucose metabolism.

What the researchers found

After 12 weeks of liraglutide monotherapy (0.6-1.8 mg/day) in 71 obese subjects:

- Significant weight loss (p<0.001)

- Fasting blood glucose, 2-hour post-load glucose, and HbA1c all significantly improved (all p<0.001)

- Subcutaneous adipose tissue (SAT): significantly reduced (p<0.001)

- Visceral adipose tissue (VAT): significantly reduced (p<0.001)

- Liver fat content (LFC): significantly reduced (p<0.001)

Subgroup analysis:

- Patients with impaired glucose regulation (IGR) had higher baseline liver fat than those with normal glucose tolerance (NGT) (p=0.002)

- IGR patients showed significantly greater liver fat reduction than NGT patients (p<0.001)

- Liver fat reduction correlated with fasting glucose improvement (r=0.587, p<0.001) and HbA1c improvement (r=0.607, p<0.001)

Why it matters

Non-alcoholic fatty liver disease (NAFLD) affects roughly 25% of the global population and is a leading cause of liver cirrhosis. This study provides MRI-based evidence that liraglutide effectively reduces liver fat in obese patients — and that the patients who benefit most are those with pre-diabetes, who also have the highest liver fat. This supports using GLP-1 medications as a targeted therapy for obese patients with fatty liver and metabolic syndrome.

How the study worked

Prospective single-arm clinical study in 71 obese Chinese subjects receiving liraglutide monotherapy (titrated from 0.6 mg to 1.8 mg daily) for 12 weeks. Clinical assessments, blood tests, and MRI examinations were performed at baseline and 12 weeks. MRI measured abdominal fat distribution using proton-density fat fraction (PDFF) — a precise quantitative technique for liver fat, visceral fat, and subcutaneous fat.

What this study cannot tell us

This is a single-arm study without a placebo control group, so the observed improvements cannot be definitively attributed to liraglutide versus natural lifestyle changes or regression to the mean. The sample size is relatively small (n=71). The 12-week duration may not reflect long-term outcomes. The study population was exclusively Chinese, limiting generalizability. Specific liraglutide doses within the 0.6-1.8 mg range were not analyzed separately. No liver biopsy was performed to assess inflammation or fibrosis changes.

How to read the evidence

This is a prospective single-arm clinical study without a control group. While the MRI-based fat quantification provides objective, high-quality endpoint measurements, the lack of a placebo or comparator arm limits causal interpretation. It provides moderate evidence supporting liraglutide's effects on abdominal and liver fat.

When this study was published

Published in 2024, this is a recent study that adds MRI-quantified evidence to the growing literature on GLP-1 medications and fatty liver disease, particularly in an Asian population.

The bigger picture

GLP-1 receptor agonists are increasingly recognized for their liver-protective effects beyond weight loss. Semaglutide is now in late-stage clinical trials for non-alcoholic steatohepatitis (NASH), and this study adds MRI-quantified evidence that the related drug liraglutide also reduces liver fat. The strong correlation between liver fat reduction and glucose improvement suggests these effects are mechanistically linked — potentially through reduced hepatic insulin resistance. This positions GLP-1 medications as multi-organ metabolic therapies.

Questions still open

Would the liver fat reduction from liraglutide persist beyond 12 weeks, and would it prevent progression to liver fibrosis?
How does liraglutide's liver fat reduction compare to semaglutide or tirzepatide in head-to-head studies?
Is the strong correlation between liver fat reduction and glucose improvement driven by reduced hepatic insulin resistance?

Common questions

Can liraglutide reduce fatty liver?

Yes — this study used MRI to precisely measure liver fat before and after 12 weeks of liraglutide treatment, and found a significant reduction. Patients with pre-diabetes (who had the most liver fat to begin with) saw the greatest reduction. The decrease in liver fat was strongly correlated with improvements in blood sugar control, suggesting these benefits are linked. While liraglutide isn't approved specifically for fatty liver disease, these findings support its use as a metabolic therapy that benefits the liver.

Does liraglutide reduce belly fat specifically?

Yes — this study used MRI to separately measure two types of belly fat: visceral fat (around internal organs, the most dangerous type) and subcutaneous fat (under the skin). Both types were significantly reduced after 12 weeks of liraglutide. This is important because visceral fat is more strongly linked to diabetes, heart disease, and liver problems than subcutaneous fat or overall body weight.

Read the original research

Effects of liraglutide on abdominal fat distribution and glucose metabolism in Chinese subjects with obesity.

Diabetology & metabolic syndrome, 16(1), 307

View on PubMed ↗Publisher’s paper ↗

Citation

Du, Mengyang; Yue, Jiang; Qi, Yicheng; He, Shengyun; Lu, Xiaobing; Yang, Minglan; Wang, Lihua; Lu, Qing; Ma, Jing. (2024). Effects of liraglutide on abdominal fat distribution and glucose metabolism in Chinese subjects with obesity.. Diabetology & metabolic syndrome, 16(1), 307. https://doi.org/10.1186/s13098-024-01540-4